We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current XPH market cap is 217.12M. The company's latest EPS is USD -0.1280 and P/E is -346.72.
| Quarter End | |||||
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | |||||
| Operating Income | |||||
| Net Income |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 2.11M | 2.24M | 3.42M | 3.54M | 3.95M |
| Operating Income | 0 | 0 | 0 | 0 | 0 |
| Net Income | 16.95M | 46.43M | -42.2M | -5.01M | -627k |
| Quarter End | |||||
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | |||||
| Total Liabilities | |||||
| Total Equity |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 253.63M | 288.58M | 211.12M | 229.91M | 206.3M |
| Total Liabilities | 10.19M | 16.87M | 5.19M | 8.34M | 11.16M |
| Total Equity | 243.44M | 271.72M | 205.93M | 221.57M | 195.15M |
| Market Cap | 217.12M |
| Price to Earnings Ratio | -346.72 |
| Price to Sales Ratio | 55.07 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 1.11 |
| Dividend Yield | - |
| Shares Outstanding | 4.9M |
| Average Volume (1 week) | 26.68k |
| Average Volume (1 Month) | 27.75k |
| 52 Week Change | -1.60% |
| 52 Week High | 48.76 |
| 52 Week Low | 38.88 |
| Spread (Intraday) | 1.55 (3.44%) |
| Company Name | SPDR S&P Pharmaceuticals |
| Address |
one iron street boston, massachusetts 02210 |
| Website | https://www.ssga.com |
| Industry | mgmt invt offices, open-end (6722) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
